Identification

Name
Bumetanide
Accession Number
DB00887  (APRD00294)
Type
Small Molecule
Groups
Approved
Description

A sulfamyl diuretic. [PubChem]

Structure
Thumb
Synonyms
  • 3-(Aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid
  • 3-Butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid
  • 3-Butylamino-4-phenoxy-5-sulfamoyl-benzoic acid
  • 3-Butylamino-4-phenoxy-5-sulfamoylbenzoic acid
  • Bumetanida
  • Bumetanidum
External IDs
a684051 / CS 380 / Ro 10-6338 / RO-10-6338
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Burinex - Tab 2mgTablet2 mgOralLeo Pharma1996-12-312004-07-23Canada
Burinex Tab 1mgTablet1 mgOralLeo Pharma1993-12-31Not applicableCanada
Burinex Tab 5mgTablet5 mgOralLeo Pharma1993-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BumetanideTablet2 mg/1OralAvera Mc Kennan Hospital2015-03-13Not applicableUs
BumetanideTablet2 mg/1OralUnit Dose Services2007-10-16Not applicableUs
BumetanideTablet2 mg/1OralAphena Pharma Solutions Tennessee, Inc.1996-11-21Not applicableUs
BumetanideTablet1 mg/1OralParagon Enterprises, Inc2016-11-162017-06-29Us
BumetanideInjection.25 mg/mLIntramuscular; IntravenousWest Ward Pharmaceutical2008-04-30Not applicableUs
BumetanideTablet1 mg/1OralEon Labs, Inc.1996-11-21Not applicableUs
BumetanideTablet1 mg/1OralAidarex Pharmaceuticals LLC2007-10-16Not applicableUs00093 4233 01 nlmimage10 322d1908
BumetanideTablet1 mg/1OralNu Care Pharmaceuticals,inc.2017-10-18Not applicableUs
BumetanideTablet1 mg/1OralZydus Pharmaceuticals Usa, Inc.2018-05-01Not applicableUs
BumetanideInjection, solution.25 mg/mLIntramuscular; IntravenousCardinal Health2011-11-16Not applicableUs
International/Other Brands
Bumex (F. Hoffmann-La Roche Ltd.) / Burinex (F. Hoffmann-La Roche Ltd.) / Fordiuran (LEO Pharma A/S) / Lunetoron (Daiichi Sankyo)
Categories
UNII
0Y2S3XUQ5H
CAS number
28395-03-1
Weight
Average: 364.416
Monoisotopic: 364.10929245
Chemical Formula
C17H20N2O5S
InChI Key
MAEIEVLCKWDQJH-UHFFFAOYSA-N
InChI
InChI=1S/C17H20N2O5S/c1-2-3-9-19-14-10-12(17(20)21)11-15(25(18,22)23)16(14)24-13-7-5-4-6-8-13/h4-8,10-11,19H,2-3,9H2,1H3,(H,20,21)(H2,18,22,23)
IUPAC Name
3-(butylamino)-4-phenoxy-5-sulfamoylbenzoic acid
SMILES
CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O

Pharmacology

Indication

For the treatment of edema associated with congestive heart failure, hepatic and renal disease including the nephrotic syndrome.

Structured Indications
Pharmacodynamics

Bumetanide is a loop diuretic of the sulfamyl category to treat heart failure. It is often used in patients in whom high doses of furosemide are ineffective. There is however no reason not to use bumetanide as a first choice drug. The main difference between the two substances is in bioavailability. It is said to be a more predictable diuretic, meaning that the predictable absorption is reflected in a more predictable effect. Bumetanide is 40 times more potent than furosemide (for patients with normal renal function).

Mechanism of action

Bumetanide interferes with renal cAMP and/or inhibits the sodium-potassium ATPase pump. Bumetanide appears to block the active reabsorption of chloride and possibly sodium in the ascending loop of Henle, altering electrolyte transfer in the proximal tubule. This results in excretion of sodium, chloride, and water and, hence, diuresis.

TargetActionsOrganism
ASolute carrier family 12 member 1
inhibitor
Human
ASolute carrier family 12 member 2
inhibitor
Human
ASolute carrier family 12 member 4
inhibitor
Human
ASolute carrier family 12 member 5
inhibitor
Human
UCystic fibrosis transmembrane conductance regulator
antagonist
Human
Absorption

Bumetanide is completely absorbed (80%), and the absorption is not altered when taken with food. Bioavailability is almost complete.

Volume of distribution
Not Available
Protein binding

97%

Metabolism

45% is secreted unchanged. Urinary and biliary metabolites are formed by oxidation of the N-butyl side chain.

Route of elimination

Oral administration of carbon-14 labeled Bumex to human volunteers revealed that 81% of the administered radioactivity was excreted in the urine, 45% of it as unchanged drug. Biliary excretion of Bumex amounted to only 2% of the administered dose.

Half life

60-90 minutes

Clearance
  • 0.2 - 1.1 mL/min/kg [preterm and full-term neonates with respiratory disorders]
  • 2.17 mL/min/kg [neonates receiving bumetanide for volume overload]
  • 1.8 +/- 0.3 mL/min/kg [geriatric subjects]
  • 2.9 +/- 0.2 mL/min/kg [younger subjects]
Toxicity

Overdosage can lead to acute profound water loss, volume and electrolyte depletion, dehydration, reduction of blood volume and circulatory collapse with a possibility of vascular thrombosis and embolism. Electrolyte depletion may be manifested by weakness, dizziness, mental confusion, anorexia, lethargy, vomiting and cramps. Treatment consists of replacement of fluid and electrolyte losses by careful monitoring of the urine and electrolyte output and serum electrolyte levels.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Bumetanide Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe therapeutic efficacy of Bumetanide can be decreased when used in combination with (4R)-limonene.Investigational
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the hypokalemic activities of Bumetanide.Investigational
19-norandrostenedione19-norandrostenedione may increase the hypokalemic activities of Bumetanide.Experimental, Illicit
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Bumetanide.Investigational
5-androstenedione5-androstenedione may increase the hypokalemic activities of Bumetanide.Experimental, Illicit
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Bumetanide.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Bumetanide is combined with Acebutolol.Approved, Investigational
AceclofenacThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Aceclofenac.Approved, Investigational
AcemetacinThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Bumetanide.Approved, Investigational, Withdrawn
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Acetyldigitoxin.Approved
AcetyldigoxinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Acetyldigoxin.Experimental
Acetylsalicylic acidThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AclarubicinThe serum concentration of Aclarubicin can be increased when it is combined with Bumetanide.Investigational
AdapaleneThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Adapalene.Approved
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Bumetanide.Experimental, Investigational
AlclofenacThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Alclofenac.Approved, Withdrawn
AlclometasoneAlclometasone may increase the hypokalemic activities of Bumetanide.Approved
AlcuroniumBumetanide may decrease the neuromuscular blocking activities of Alcuronium.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Bumetanide.Approved
AldosteroneAldosterone may increase the hypokalemic activities of Bumetanide.Experimental, Investigational
AldoxorubicinThe serum concentration of Aldoxorubicin can be increased when it is combined with Bumetanide.Investigational
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Bumetanide.Approved, Illicit
AliskirenThe risk or severity of adverse effects can be increased when Bumetanide is combined with Aliskiren.Approved, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Bumetanide.Investigational
AllopurinolThe risk or severity of adverse effects can be increased when Bumetanide is combined with Allopurinol.Approved
AlminoprofenThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Alminoprofen.Experimental
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Bumetanide.Approved
AloxiprinThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Aloxiprin.Experimental
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Bumetanide.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Bumetanide.Illicit
AmcinonideAmcinonide may increase the hypokalemic activities of Bumetanide.Approved
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Bumetanide.Approved, Investigational
AmikacinThe serum concentration of Amikacin can be increased when it is combined with Bumetanide.Approved, Investigational, Vet Approved
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Bumetanide.Approved
Aminosalicylic AcidThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Aminosalicylic Acid.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Bumetanide.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Bumetanide.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Bumetanide.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Bumetanide.Approved, Investigational
AmrubicinThe serum concentration of Amrubicin can be increased when it is combined with Bumetanide.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Bumetanide is combined with Amyl Nitrite.Approved
AndrographolideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Andrographolide.Investigational
AndrostenedioneAndrostenedione may increase the hypokalemic activities of Bumetanide.Experimental, Illicit
AnecortaveAnecortave may increase the hypokalemic activities of Bumetanide.Investigational
anecortave acetateanecortave acetate may increase the hypokalemic activities of Bumetanide.Investigational
AnisodamineThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Anisodamine.Investigational
AnnamycinThe serum concentration of Annamycin can be increased when it is combined with Bumetanide.Investigational
AntipyrineThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Antipyrine.Approved, Investigational
ApocyninThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Apocynin.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Bumetanide.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Apraclonidine.Approved
ApramycinThe serum concentration of Apramycin can be increased when it is combined with Bumetanide.Experimental, Vet Approved
ApremilastThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Apremilast.Approved, Investigational
ArbekacinThe serum concentration of Arbekacin can be increased when it is combined with Bumetanide.Approved, Investigational
ArbutamineArbutamine may increase the hypokalemic activities of Bumetanide.Approved
ArformoterolArformoterol may increase the hypokalemic activities of Bumetanide.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Bumetanide.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Bumetanide.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Bumetanide.Approved, Investigational
AtamestaneAtamestane may increase the hypokalemic activities of Bumetanide.Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Bumetanide.Approved
AtracuriumBumetanide may decrease the neuromuscular blocking activities of Atracurium.Approved, Experimental, Investigational
Atracurium besylateBumetanide may decrease the neuromuscular blocking activities of Atracurium besylate.Approved
AzapropazoneThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Azapropazone.Withdrawn
AzelastineThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Bumetanide is combined with Azilsartan medoxomil.Approved, Investigational
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Bumetanide.Investigational
BalsalazideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Balsalazide.Approved, Investigational
BambuterolBambuterol may increase the hypokalemic activities of Bumetanide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Bumetanide.Experimental
BarbitalBarbital may increase the hypotensive activities of Bumetanide.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Bumetanide.Approved
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Bumetanide.Approved, Investigational
BekanamycinThe serum concentration of Bekanamycin can be increased when it is combined with Bumetanide.Experimental
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Bumetanide.Investigational
BenazeprilBumetanide may increase the hypotensive activities of Benazepril.Approved, Investigational
BendazacThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Bendazac.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Bumetanide.Approved
BenorilateThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Benorilate.Experimental
BenoxaprofenThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Benoxaprofen.Withdrawn
BenzydamineThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Benzydamine.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Bumetanide.Approved, Withdrawn
BetamethasoneBetamethasone may increase the hypokalemic activities of Bumetanide.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Bumetanide.Approved, Investigational
BevoniumThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Bevonium.Experimental
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Bumetanide.Experimental, Illicit, Withdrawn
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Bumetanide.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Bumetanide.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Bumetanide is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Bumetanide.Approved
BromfenacThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Bromfenac.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Bumetanide.Approved, Investigational
BucillamineThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Bucillamine.Investigational
BudesonideBudesonide may increase the hypokalemic activities of Bumetanide.Approved
BufexamacThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Bufexamac.Approved, Experimental
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Bumetanide.Investigational, Withdrawn
BumadizoneThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Bumadizone.Experimental
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Bumetanide.Approved, Investigational
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Bumetanide.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Bumetanide.Approved, Illicit, Vet Approved
CanagliflozinThe risk or severity of hypotension can be increased when Canagliflozin is combined with Bumetanide.Approved
Candesartan cilexetilThe risk or severity of hypotension can be increased when Candesartan cilexetil is combined with Bumetanide.Approved
CandoxatrilBumetanide may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilBumetanide may increase the hypotensive activities of Captopril.Approved
Carbaspirin calciumThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Carbaspirin calcium.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Bumetanide.Approved, Investigational
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Bumetanide.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Bumetanide.Illicit, Investigational, Vet Approved
CarprofenThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Bumetanide.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Bumetanide is combined with Carvedilol.Approved, Investigational
CastanospermineThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Castanospermine.Experimental
CelecoxibThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the hypokalemic activities of Bumetanide.Approved, Investigational
ChloroquineThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Chloroquine.Approved, Investigational, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Bumetanide.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Bumetanide.Approved, Investigational, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Bumetanide.Approved, Investigational
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Bumetanide.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Bumetanide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Choline magnesium trisalicylate.Approved
CiclesonideCiclesonide may increase the hypokalemic activities of Bumetanide.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Bumetanide.Experimental
CilazaprilBumetanide may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Bumetanide.Approved, Investigational
CisatracuriumBumetanide may decrease the neuromuscular blocking activities of Cisatracurium.Approved
CisplatinThe risk or severity of ototoxicity and nephrotoxicity can be increased when Bumetanide is combined with Cisplatin.Approved
ClenbuterolClenbuterol may increase the hypokalemic activities of Bumetanide.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Clevidipine.Approved, Investigational
ClobetasolClobetasol may increase the hypokalemic activities of Bumetanide.Approved, Investigational
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Bumetanide.Approved
ClobetasoneClobetasone may increase the hypokalemic activities of Bumetanide.Approved
ClocortoloneClocortolone may increase the hypokalemic activities of Bumetanide.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Bumetanide.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Bumetanide.Approved, Investigational, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Bumetanide.Approved
ClonixinThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Clonixin.Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Bumetanide.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Bumetanide.Approved, Illicit
ColesevelamColesevelam can cause a decrease in the absorption of Bumetanide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Bumetanide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Bumetanide.Approved, Investigational
Cortexolone 17α-propionateCortexolone 17α-propionate may increase the hypokalemic activities of Bumetanide.Investigational
CorticosteroneCorticosterone may increase the hypokalemic activities of Bumetanide.Experimental
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Bumetanide.Approved, Investigational
CurcuminThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Curcumin.Approved, Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Bumetanide.Approved, Investigational, Vet Approved
CymarinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Cymarin.Experimental
DapagliflozinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Dapagliflozin.Approved
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Bumetanide.Approved
DecamethoniumBumetanide may decrease the neuromuscular blocking activities of Decamethonium.Approved
DeflazacortDeflazacort may increase the hypokalemic activities of Bumetanide.Approved, Investigational
DelaprilBumetanide may increase the hypotensive activities of Delapril.Experimental
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Bumetanide.Investigational
DersalazineThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Dersalazine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Bumetanide.Approved
DeslanosideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Deslanoside.Approved
DesonideDesonide may increase the hypokalemic activities of Bumetanide.Approved, Investigational
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Bumetanide.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Bumetanide.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the hypokalemic activities of Bumetanide.Experimental, Vet Approved
DexamethasoneDexamethasone may increase the hypokalemic activities of Bumetanide.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Bumetanide.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Bumetanide.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Bumetanide.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Bumetanide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Bumetanide.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Bumetanide.Approved, Investigational
DibekacinThe serum concentration of Dibekacin can be increased when it is combined with Bumetanide.Experimental
DiclofenacThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Diclofenamide.Approved, Investigational
DifenpiramideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Difenpiramide.Experimental
DiflorasoneDiflorasone may increase the hypokalemic activities of Bumetanide.Approved
DiflunisalThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Diflunisal.Approved, Investigational
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Bumetanide.Approved, Investigational, Withdrawn
DifluprednateDifluprednate may increase the hypokalemic activities of Bumetanide.Approved
DigitoxinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Digitoxin.Approved, Investigational
DigoxinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Digoxin.Approved
Digoxin Immune Fab (Ovine)The risk or severity of adverse effects can be increased when Bumetanide is combined with Digoxin Immune Fab (Ovine).Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Bumetanide.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Bumetanide.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Bumetanide.Experimental, Illicit
DihydrostreptomycinThe serum concentration of Dihydrostreptomycin can be increased when it is combined with Bumetanide.Investigational, Vet Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Bumetanide.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Bumetanide is combined with Dinutuximab.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Bumetanide.Approved, Illicit
DipivefrinDipivefrin may increase the hypokalemic activities of Bumetanide.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Bumetanide is combined with Dipyridamole.Approved
DobutamineDobutamine may increase the hypokalemic activities of Bumetanide.Approved
DofetilideThe risk or severity of QTc prolongation, torsade de pointes, hypokalemia, hypomagnesemia, and cardiac arrest can be increased when Bumetanide is combined with Dofetilide.Approved, Investigational
Domoic AcidBumetanide may decrease the neuromuscular blocking activities of Domoic Acid.Experimental
Doxacurium chlorideBumetanide may decrease the neuromuscular blocking activities of Doxacurium chloride.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Bumetanide.Approved
DoxofyllineDoxofylline may increase the hypokalemic activities of Bumetanide.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Bumetanide.Approved, Investigational
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Bumetanide.Experimental
DroxicamThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Droxicam.Withdrawn
DroxidopaDroxidopa may increase the hypokalemic activities of Bumetanide.Approved, Investigational
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Bumetanide.Approved, Investigational
DuloxetineBumetanide may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Duvelisib.Investigational
E-6201The therapeutic efficacy of Bumetanide can be decreased when used in combination with E-6201.Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Bumetanide.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Empagliflozin.Approved
EnalaprilBumetanide may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatBumetanide may increase the hypotensive activities of Enalaprilat.Approved
EphedraEphedra may increase the hypokalemic activities of Bumetanide.Approved, Nutraceutical, Withdrawn
EpinephrineEpinephrine may increase the hypokalemic activities of Bumetanide.Approved, Vet Approved
EpirizoleThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Epirizole.Approved
EpirubicinThe serum concentration of Epirubicin can be increased when it is combined with Bumetanide.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Bumetanide.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Bumetanide.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Bumetanide.Approved
EquileninEquilenin may increase the hypokalemic activities of Bumetanide.Experimental
EquilinEquilin may increase the hypokalemic activities of Bumetanide.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Bumetanide.Approved
EstroneEstrone may increase the hypokalemic activities of Bumetanide.Approved
Estrone sulfateEstrone sulfate may increase the hypokalemic activities of Bumetanide.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Bumetanide is combined with Etacrynic acid.Approved, Investigational
EtafedrineEtafedrine may increase the hypokalemic activities of Bumetanide.Approved
EtanerceptThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Etanercept.Approved, Investigational
EthenzamideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Ethenzamide.Experimental
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Bumetanide.Approved, Illicit
EtodolacThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Etofenamate.Approved, Investigational
EtoricoxibThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Etoricoxib.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Bumetanide.Illicit, Vet Approved
Evening primrose oilThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Evening primrose oil.Investigational, Nutraceutical
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Bumetanide.Approved, Investigational
ExisulindThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Exisulind.Investigational
FelbinacThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Felbinac.Experimental
FelodipineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Felodipine.Approved, Investigational
FenbufenThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Fenbufen.Approved
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Bumetanide.Approved
FenoprofenThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Fenoprofen.Approved
FenoterolFenoterol may increase the hypokalemic activities of Bumetanide.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Bumetanide.Approved, Illicit, Investigational, Vet Approved
FentiazacThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Fentiazac.Experimental
FeprazoneThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Feprazone.Experimental
Ferulic acidThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Bumetanide.Approved, Investigational
FloctafenineThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Floctafenine.Approved, Withdrawn
FluasteroneFluasterone may increase the hypokalemic activities of Bumetanide.Investigational
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Bumetanide.Approved, Investigational
FlumethasoneFlumethasone may increase the hypokalemic activities of Bumetanide.Approved, Vet Approved
FlunisolideFlunisolide may increase the hypokalemic activities of Bumetanide.Approved, Investigational
FlunixinThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Flunixin.Vet Approved
FlunoxaprofenThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Flunoxaprofen.Experimental
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Bumetanide.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the hypokalemic activities of Bumetanide.Approved, Investigational
FluocortoloneFluocortolone may increase the hypokalemic activities of Bumetanide.Approved, Withdrawn
FluorometholoneFluorometholone may increase the hypokalemic activities of Bumetanide.Approved, Investigational
FluprednideneFluprednidene may increase the hypokalemic activities of Bumetanide.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Bumetanide.Approved
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Bumetanide.Approved
FlurbiprofenThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Flurbiprofen.Approved, Investigational
Fluticasone furoateFluticasone furoate may increase the hypokalemic activities of Bumetanide.Approved
Fluticasone propionateFluticasone propionate may increase the hypokalemic activities of Bumetanide.Approved
FormestaneFormestane may increase the hypokalemic activities of Bumetanide.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the hypokalemic activities of Bumetanide.Approved, Investigational
FoscarnetBumetanide may decrease the excretion rate of Foscarnet which could result in a higher serum level.Approved
FosinoprilBumetanide may increase the hypotensive activities of Fosinopril.Approved
FosphenytoinFosphenytoin may decrease the diuretic activities of Bumetanide.Approved, Investigational
FramycetinThe serum concentration of Framycetin can be increased when it is combined with Bumetanide.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Bumetanide.Approved, Vet Approved
GallamineBumetanide may decrease the neuromuscular blocking activities of Gallamine.Experimental
Gallamine TriethiodideBumetanide may decrease the neuromuscular blocking activities of Gallamine Triethiodide.Approved
GeneticinThe serum concentration of Geneticin can be increased when it is combined with Bumetanide.Experimental
GentamicinThe serum concentration of Gentamicin can be increased when it is combined with Bumetanide.Approved, Vet Approved
GENTAMICIN C1AThe serum concentration of GENTAMICIN C1A can be increased when it is combined with Bumetanide.Experimental
GitoformateThe risk or severity of adverse effects can be increased when Bumetanide is combined with Gitoformate.Experimental
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Bumetanide.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Bumetanide.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Bumetanide.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Bumetanide.Approved, Investigational
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Bumetanide.Approved, Investigational
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Bumetanide.Approved
GPX-150The serum concentration of GPX-150 can be increased when it is combined with Bumetanide.Investigational
GuacetisalThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Guacetisal.Experimental
GuanfacineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Guanfacine.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Bumetanide.Investigational
HalcinonideHalcinonide may increase the hypokalemic activities of Bumetanide.Approved, Investigational, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Bumetanide.Approved, Vet Approved
HE3286HE3286 may increase the hypokalemic activities of Bumetanide.Investigational
Hemoglobin crosfumarilThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Hemoglobin crosfumaril.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Bumetanide.Approved, Illicit, Investigational
HexobarbitalHexobarbital may increase the hypotensive activities of Bumetanide.Approved
HigenamineThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Higenamine.Investigational
HydralazineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Bumetanide.Approved, Illicit
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Bumetanide.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Bumetanide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Bumetanide.Approved, Illicit
Hygromycin BThe serum concentration of Hygromycin B can be increased when it is combined with Bumetanide.Vet Approved
IbuprofenThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Ibuproxam.Withdrawn
IcatibantThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Icatibant.Approved, Investigational
IdarubicinThe serum concentration of Idarubicin can be increased when it is combined with Bumetanide.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Bumetanide.Approved, Investigational
ImidaprilBumetanide may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Imidazole salicylate.Experimental
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Bumetanide.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Bumetanide.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Bumetanide.Approved
IndobufenThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Indobufen.Investigational
IndomethacinThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Indoprofen.Withdrawn
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Bumetanide.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Bumetanide.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Bumetanide.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Bumetanide.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Bumetanide.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Bumetanide.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Bumetanide.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Bumetanide.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Bumetanide is combined with Irbesartan.Approved, Investigational
IsepamicinThe serum concentration of Isepamicin can be increased when it is combined with Bumetanide.Experimental
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Bumetanide.Approved
IsoetarineIsoetarine may increase the hypokalemic activities of Bumetanide.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Bumetanide.Approved, Vet Approved
IsoprenalineIsoprenaline may increase the hypokalemic activities of Bumetanide.Approved, Investigational
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Bumetanide.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Bumetanide is combined with Isosorbide Mononitrate.Approved
IsoxicamThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Bumetanide.Approved, Investigational
IstaroximeIstaroxime may increase the hypokalemic activities of Bumetanide.Investigational
IvabradineBumetanide may increase the arrhythmogenic activities of Ivabradine.Approved
KanamycinThe serum concentration of Kanamycin can be increased when it is combined with Bumetanide.Approved, Investigational, Vet Approved
KebuzoneThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Kebuzone.Experimental
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Bumetanide.Approved, Investigational
KetoprofenThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Bumetanide.Approved
LacidipineBumetanide may increase the hypotensive activities of Lacidipine.Approved, Investigational
Lanatoside CThe risk or severity of adverse effects can be increased when Bumetanide is combined with Lanatoside C.Experimental
LeflunomideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Leflunomide.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Bumetanide.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Bumetanide is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Bumetanide.Approved, Investigational
LevodopaBumetanide may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Bumetanide.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Bumetanide.Approved
LevosalbutamolLevosalbutamol may increase the hypokalemic activities of Bumetanide.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Bumetanide.Approved, Investigational
LicoriceThe risk or severity of hypokalemia can be increased when Licorice is combined with Bumetanide.Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Bumetanide.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Bumetanide.Approved
LisinoprilBumetanide may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisofyllineThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be decreased when it is combined with Bumetanide.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Bumetanide.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Bumetanide.Approved, Investigational
LonazolacThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Lonazolac.Experimental
LornoxicamThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Bumetanide.Approved
LoteprednolLoteprednol may increase the hypokalemic activities of Bumetanide.Approved
LoxoprofenThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Loxoprofen.Approved, Investigational
LumiracoxibThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Lumiracoxib.Approved, Investigational
Magnesium salicylateThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Magnesium salicylate.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Bumetanide.Approved, Investigational
MasoprocolThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Masoprocol.Approved, Investigational
ME-609ME-609 may increase the hypokalemic activities of Bumetanide.Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Mecamylamine.Approved, Investigational
Meclofenamic acidThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
MedrysoneMedrysone may increase the hypokalemic activities of Bumetanide.Approved
Mefenamic acidThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Mefenamic acid.Approved
MelengestrolMelengestrol may increase the hypokalemic activities of Bumetanide.Vet Approved
MeloxicamThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Bumetanide.Experimental
MesalazineThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Metamizole.Approved, Investigational, Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Bumetanide.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Bumetanide.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Bumetanide.Approved, Illicit
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Bumetanide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Bumetanide.Approved
MethotrexateThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Methotrexate.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Bumetanide.Approved
Methyl salicylateThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Methyl salicylate.Approved, Vet Approved
MethyldopaThe risk or severity of adverse effects can be increased when Bumetanide is combined with Methyldopa.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Bumetanide.Approved
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Bumetanide.Approved, Vet Approved
MetildigoxinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Metildigoxin.Experimental
MetipranololThe risk or severity of adverse effects can be increased when Bumetanide is combined with Metipranolol.Approved
MetocurineBumetanide may decrease the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideBumetanide may decrease the neuromuscular blocking activities of Metocurine Iodide.Approved, Withdrawn
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Bumetanide.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Bumetanide.Approved, Investigational
MetrizamideThe serum concentration of Metrizamide can be increased when it is combined with Bumetanide.Approved
MicronomicinThe serum concentration of Micronomicin can be increased when it is combined with Bumetanide.Experimental
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Bumetanide.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Bumetanide.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Bumetanide.Approved, Investigational
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Bumetanide.Approved, Investigational
MivacuriumBumetanide may decrease the neuromuscular blocking activities of Mivacurium.Approved
MizoribineThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Mizoribine.Investigational
MoexiprilBumetanide may increase the hypotensive activities of Moexipril.Approved
MofebutazoneThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Mofebutazone.Experimental
MometasoneMometasone may increase the hypokalemic activities of Bumetanide.Approved, Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Bumetanide.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Bumetanide.Approved, Investigational
Mycophenolate mofetilThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Bumetanide.Approved, Investigational
NabumetoneThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Bumetanide is combined with Nadolol.Approved
NafamostatThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Nafamostat.Approved, Investigational
NaftifineThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Naftifine.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Bumetanide.Approved
NaproxenThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Naproxen.Approved, Vet Approved
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Bumetanide.Approved, Investigational
NCX 1022NCX 1022 may increase the hypokalemic activities of Bumetanide.Investigational
NeamineThe serum concentration of Neamine can be increased when it is combined with Bumetanide.Experimental
NebivololThe risk or severity of adverse effects can be increased when Bumetanide is combined with Nebivolol.Approved, Investigational
NeomycinThe serum concentration of Neomycin can be increased when it is combined with Bumetanide.Approved, Vet Approved
NeosaxitoxinBumetanide may decrease the neuromuscular blocking activities of Neosaxitoxin.Investigational
NepafenacThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Nepafenac.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Nesiritide.Approved, Investigational
NetilmicinThe serum concentration of Netilmicin can be increased when it is combined with Bumetanide.Approved, Investigational
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Bumetanide.Approved, Investigational
NicomorphineThe risk or severity of adverse effects can be increased when Nicomorphine is combined with Bumetanide.Experimental
NicorandilNicorandil may increase the hypotensive activities of Bumetanide.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Nifedipine.Approved
NifenazoneThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Nifenazone.Experimental
Niflumic AcidThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Niflumic Acid.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Bumetanide.Approved, Investigational
NimesulideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Bumetanide.Approved, Investigational
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Bumetanide.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Bumetanide.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Bumetanide.Approved
NitroaspirinThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Bumetanide.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Bumetanide.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Nitrous acid is combined with Bumetanide.Approved, Investigational
NorepinephrineNorepinephrine may increase the hypokalemic activities of Bumetanide.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Bumetanide.Approved, Illicit
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Bumetanide.Approved, Investigational
OleandrinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Oleandrin.Experimental, Investigational
Oleoyl-estroneOleoyl-estrone may increase the hypokalemic activities of Bumetanide.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Bumetanide.Approved, Investigational
OlodaterolOlodaterol may increase the hypokalemic activities of Bumetanide.Approved
OlopatadineThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Olopatadine.Approved
OlsalazineThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Olsalazine.Approved
OmapatrilatBumetanide may increase the hypotensive activities of Omapatrilat.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Bumetanide.Approved, Illicit
OrciprenalineOrciprenaline may increase the hypokalemic activities of Bumetanide.Approved
OrgoteinThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Orgotein.Vet Approved
OuabainThe risk or severity of adverse effects can be increased when Bumetanide is combined with Ouabain.Approved
OxaprozinThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Oxaprozin.Approved
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Bumetanide.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Bumetanide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Bumetanide.Approved, Investigational, Vet Approved
OxyphenbutazoneThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Oxyphenbutazone.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Bumetanide.Approved, Vet Approved
PancuroniumBumetanide may decrease the neuromuscular blocking activities of Pancuronium.Approved
PapaverineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Papaverine.Approved, Investigational
ParamethasoneParamethasone may increase the hypokalemic activities of Bumetanide.Approved
ParecoxibThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Parecoxib.Approved
ParomomycinThe serum concentration of Paromomycin can be increased when it is combined with Bumetanide.Approved, Investigational
ParthenolideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Parthenolide.Approved, Investigational
PenbutololThe risk or severity of adverse effects can be increased when Bumetanide is combined with Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Bumetanide.Approved, Vet Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Bumetanide.Approved, Investigational, Vet Approved
PerindoprilBumetanide may increase the hypotensive activities of Perindopril.Approved
PeruvosideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Peruvoside.Experimental
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Bumetanide.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Bumetanide.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Bumetanide.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Bumetanide.Approved, Investigational, Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Bumetanide.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Bumetanide.Experimental
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Bumetanide.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Bumetanide.Approved
Phenyl aminosalicylateThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Phenyl aminosalicylate.Approved
PhenylbutazoneThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Bumetanide.Approved, Vet Approved, Withdrawn
PhenytoinPhenytoin may decrease the diuretic activities of Bumetanide.Approved, Vet Approved
PimecrolimusThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PindololThe risk or severity of adverse effects can be increased when Bumetanide is combined with Pindolol.Approved, Investigational
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Bumetanide.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Bumetanide.Approved, Investigational
PipecuroniumBumetanide may decrease the neuromuscular blocking activities of Pipecuronium.Approved
PirarubicinThe serum concentration of Pirarubicin can be increased when it is combined with Bumetanide.Investigational
PirbuterolPirbuterol may increase the hypokalemic activities of Bumetanide.Approved
PirfenidoneThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Pirfenidone.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Bumetanide.Approved, Investigational
PiroxicamThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Piroxicam.Approved, Investigational
PirprofenThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Pirprofen.Experimental
PlazomicinThe serum concentration of Plazomicin can be increased when it is combined with Bumetanide.Investigational
PlicamycinThe serum concentration of Plicamycin can be increased when it is combined with Bumetanide.Approved, Investigational, Withdrawn
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Bumetanide.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Bumetanide.Approved, Investigational
PranoprofenThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Pranoprofen.Experimental, Investigational
PrasteronePrasterone may increase the hypokalemic activities of Bumetanide.Approved, Investigational, Nutraceutical
Prasterone sulfatePrasterone sulfate may increase the hypokalemic activities of Bumetanide.Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Bumetanide.Approved
PrednicarbatePrednicarbate may increase the hypokalemic activities of Bumetanide.Approved, Investigational
PrednisolonePrednisolone may increase the hypokalemic activities of Bumetanide.Approved, Vet Approved
PrednisonePrednisone may increase the hypokalemic activities of Bumetanide.Approved, Vet Approved
PregnenolonePregnenolone may increase the hypokalemic activities of Bumetanide.Approved, Experimental, Investigational
PrimidonePrimidone may increase the hypotensive activities of Bumetanide.Approved, Vet Approved
ProbenecidThe risk or severity of adverse effects can be increased when Probenecid is combined with Bumetanide.Approved, Investigational
ProcaterolProcaterol may increase the hypokalemic activities of Bumetanide.Approved, Investigational
ProglumetacinThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Proglumetacin.Experimental
PropacetamolThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Propacetamol.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Bumetanide.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Bumetanide.Approved, Investigational
PropyphenazoneThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Propyphenazone.Experimental
ProquazoneThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Proquazone.Experimental
ProscillaridinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Proscillaridin.Experimental
ProtokylolProtokylol may increase the hypokalemic activities of Bumetanide.Approved, Vet Approved
PTC299The therapeutic efficacy of Bumetanide can be decreased when used in combination with PTC299.Investigational
PuromycinThe serum concentration of Puromycin can be increased when it is combined with Bumetanide.Experimental
PyrantelBumetanide may decrease the neuromuscular blocking activities of Pyrantel.Approved, Vet Approved
QuetiapineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Quetiapine.Approved
QuinaprilBumetanide may increase the hypotensive activities of Quinapril.Approved, Investigational
RacepinephrineRacepinephrine may increase the hypokalemic activities of Bumetanide.Approved
RamiprilBumetanide may increase the hypotensive activities of Ramipril.Approved
RapacuroniumBumetanide may decrease the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Bumetanide.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Bumetanide.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Bumetanide.Approved, Investigational
RescinnamineBumetanide may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Bumetanide.Approved, Investigational
ResveratrolThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Resveratrol.Approved, Experimental, Investigational
RibostamycinThe serum concentration of Ribostamycin can be increased when it is combined with Bumetanide.Approved, Investigational
RimexoloneRimexolone may increase the hypokalemic activities of Bumetanide.Approved
RiociguatThe risk or severity of adverse effects can be increased when Bumetanide is combined with Riociguat.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Bumetanide is combined with Risperidone.Approved, Investigational
RitodrineRitodrine may increase the hypokalemic activities of Bumetanide.Approved, Investigational
RocuroniumBumetanide may decrease the neuromuscular blocking activities of Rocuronium.Approved
RofecoxibThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Rofecoxib.Approved, Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Bumetanide.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Bumetanide.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Bumetanide.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Bumetanide.Approved
SabarubicinThe serum concentration of Sabarubicin can be increased when it is combined with Bumetanide.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Bumetanide.Approved
SalbutamolSalbutamol may increase the hypokalemic activities of Bumetanide.Approved, Vet Approved
SalicylamideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Salicylic acid.Approved, Investigational, Vet Approved
SalmeterolSalmeterol may increase the hypokalemic activities of Bumetanide.Approved
SalsalateThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Salsalate.Approved
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Bumetanide.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Bumetanide.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Bumetanide.Approved, Investigational, Vet Approved
SemapimodThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Semapimod.Investigational
SeratrodastThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Seratrodast.Approved
SerrapeptaseThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Serrapeptase.Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Bumetanide.Approved, Vet Approved
SisomicinThe serum concentration of Sisomicin can be increased when it is combined with Bumetanide.Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Bumetanide.Approved, Investigational
Sodium phosphateBumetanide may increase the nephrotoxic activities of Sodium phosphate.Approved
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Bumetanide.Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Bumetanide.Approved
SP1049CThe serum concentration of SP1049C can be increased when it is combined with Bumetanide.Investigational
SpectinomycinThe serum concentration of Spectinomycin can be increased when it is combined with Bumetanide.Approved, Investigational, Vet Approved
SpiraprilBumetanide may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Bumetanide.Approved
SRT501The therapeutic efficacy of Bumetanide can be decreased when used in combination with SRT501.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Bumetanide.Approved, Investigational
StreptomycinThe serum concentration of Streptomycin can be increased when it is combined with Bumetanide.Approved, Vet Approved
StreptozocinThe serum concentration of Streptozocin can be increased when it is combined with Bumetanide.Approved, Investigational
SuccinylcholineBumetanide may decrease the neuromuscular blocking activities of Succinylcholine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Bumetanide.Approved, Investigational
SulfasalazineThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Sulfasalazine.Approved
SulindacThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Sulindac.Approved, Investigational
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Bumetanide.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Sulpiride.Approved, Investigational
SuprofenThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Suprofen.Approved, Withdrawn
SuxibuzoneThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Suxibuzone.Experimental
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Bumetanide.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Bumetanide.Approved
TarenflurbilThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Tarenflurbil.Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Bumetanide is combined with Telmisartan.Approved, Investigational
TemocaprilBumetanide may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenidapThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Tenidap.Experimental
TenoxicamThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Terazosin.Approved
TerbutalineTerbutaline may increase the hypokalemic activities of Bumetanide.Approved
TeriflunomideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Teriflunomide.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Bumetanide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Bumetanide.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Bumetanide.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Bumetanide.Approved, Withdrawn
Tiaprofenic acidThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Tiaprofenic acid.Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Bumetanide.Experimental
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Bumetanide.Approved
TinoridineThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Tinoridine.Investigational
TixocortolTixocortol may increase the hypokalemic activities of Bumetanide.Approved, Withdrawn
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Bumetanide.Approved, Investigational
TobramycinThe serum concentration of Tobramycin can be increased when it is combined with Bumetanide.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Bumetanide.Approved, Investigational
TolazolineThe risk or severity of adverse effects can be increased when Tolazoline is combined with Bumetanide.Approved, Vet Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Bumetanide.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Bumetanide.Approved, Withdrawn
Tolfenamic AcidThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
TolmetinThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Tolmetin.Approved
TopiramateThe risk or severity of hypokalemia can be increased when Bumetanide is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Bumetanide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Bumetanide.Approved, Investigational
TrandolaprilBumetanide may increase the hypotensive activities of Trandolapril.Approved
TranilastThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Tranilast.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Bumetanide.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Bumetanide.Approved, Investigational, Nutraceutical
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Bumetanide.Approved, Vet Approved
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Bumetanide.Approved
TribenosideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Tribenoside.Experimental
TriptolideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Triptolide.Investigational
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Bumetanide.Investigational, Withdrawn
Trolamine salicylateThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Trolamine salicylate.Approved
TubocurarineBumetanide may decrease the neuromuscular blocking activities of Tubocurarine.Approved
UlobetasolUlobetasol may increase the hypokalemic activities of Bumetanide.Approved
ValdecoxibThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Valdecoxib.Approved, Investigational, Withdrawn
ValrubicinThe serum concentration of Valrubicin can be increased when it is combined with Bumetanide.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Bumetanide.Approved, Investigational
VecuroniumBumetanide may decrease the neuromuscular blocking activities of Vecuronium.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Bumetanide.Approved
VilanterolVilanterol may increase the hypokalemic activities of Bumetanide.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Bumetanide.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Bumetanide.Approved, Investigational
ZaltoprofenThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Zaltoprofen.Approved, Investigational
ZileutonThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Zileuton.Approved, Investigational, Withdrawn
ZofenoprilBumetanide may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Zomepirac.Withdrawn
Zoptarelin doxorubicinThe serum concentration of Zoptarelin doxorubicin can be increased when it is combined with Bumetanide.Investigational
ZorubicinThe serum concentration of Zorubicin can be increased when it is combined with Bumetanide.Experimental
Food Interactions
  • Take with food to reduce irritation.

References

Synthesis Reference

Felt, P.W.; US. Patent 3,634,583; January 11, 1972; assigned to Lovens Kemiske Fabrik Produktionsaktieselskab, Denmark.

General References
Not Available
External Links
Human Metabolome Database
HMDB0015024
KEGG Drug
D00247
PubChem Compound
2471
PubChem Substance
46508147
ChemSpider
2377
BindingDB
25903
ChEBI
3213
ChEMBL
CHEMBL1072
Therapeutic Targets Database
DAP000361
PharmGKB
PA448682
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Bumetanide
ATC Codes
C03EB02 — Bumetanide and potassium-sparing agentsC03CB02 — Bumetanide and potassiumG01AE10 — Combinations of sulfonamidesC03CA02 — Bumetanide
AHFS Codes
  • 40:28.08 — Loop Diuretics
FDA label
Download (206 KB)
MSDS
Download (72.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentSeizures1
1CompletedTreatmentType 2 Diabetes Mellitus1
1, 2CompletedTreatmentNeonatal Convulsions1
1, 2RecruitingTreatmentUnresectable Hepatocellular Carcinoma1
2Not Yet RecruitingTreatmentAutism Spectrum Conditions/Disorders1
2Not Yet RecruitingTreatmentAutistic Disorder1
2TerminatedTreatmentHypokalemic Periodic Paralysis1
2, 3RecruitingHealth Services ResearchAcute Heart Failure (AHF)1
3CompletedTreatmentAutistics Children1
3WithdrawnTreatmentHeart Failure, Unspecified1
4CompletedTreatmentHeart Failure, Unspecified1
Not AvailableRecruitingTreatmentChronic Kidney Insufficiency1
Not AvailableRecruitingTreatmentCritical Care / Fluid Shifts1
Not AvailableTerminatedDiagnosticAcute Decompensated Heart Failure (ADHF)1

Pharmacoeconomics

Manufacturers
  • Baxter healthcare corp anesthesia and critical care
  • Bedford laboratories div ben venue laboratories inc
  • Hospira inc
  • Teva parenteral medicines inc
  • Validus pharmaceuticals inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Sandoz inc
Packagers
  • Advanced Pharmaceutical Services Inc.
  • Amerisource Health Services Corp.
  • Baxter International Inc.
  • Bedford Labs
  • Ben Venue Laboratories Inc.
  • Cardinal Health
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Eon Labs
  • F Hoffmann-La Roche Ltd.
  • Heartland Repack Services LLC
  • Hospira Inc.
  • Ivax Pharmaceuticals
  • Major Pharmaceuticals
  • Mckesson Corp.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Neuman Distributors Inc.
  • Nucare Pharmaceuticals Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Physicians Total Care Inc.
  • Sandhills Packaging Inc.
  • Teva Pharmaceutical Industries Ltd.
  • UDL Laboratories
  • Vangard Labs Inc.
Dosage forms
FormRouteStrength
InjectionIntramuscular; Intravenous.25 mg/mL
Injection, solutionIntramuscular; Intravenous.25 mg/mL
Injection, solutionIntravenous.25 mg/mL
TabletOral.5 mg/1
TabletOral1 mg/1
TabletOral2 mg/1
TabletOral2 mg
TabletOral1 mg
TabletOral5 mg
Prices
Unit descriptionCostUnit
Bumex 2 mg tablet1.65USD tablet
Bumetanide 2 mg tablet1.04USD tablet
Bumex 1 mg tablet0.98USD tablet
Bumex 0.5 mg tablet0.7USD tablet
Bumetanide 1 mg tablet0.51USD tablet
Bumetanide 0.5 mg tablet0.38USD tablet
Bumetanide 0.25 mg/ml vial0.25USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)230-231Felt, P.W.; US. Patent 3,634,583; January 11, 1972; assigned to Lovens Kemiske Fabrik Produktionsaktieselskab, Denmark.
water solubility>20 mg/mL (in base)Not Available
logP2.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0257 mg/mLALOGPS
logP3.44ALOGPS
logP2.42ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)4.69ChemAxon
pKa (Strongest Basic)2.7ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area118.72 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity95.78 m3·mol-1ChemAxon
Polarizability37.21 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9967
Blood Brain Barrier-0.6636
Caco-2 permeable-0.6492
P-glycoprotein substrateNon-substrate0.509
P-glycoprotein inhibitor INon-inhibitor0.8765
P-glycoprotein inhibitor IINon-inhibitor0.8103
Renal organic cation transporterNon-inhibitor0.8966
CYP450 2C9 substrateNon-substrate0.6368
CYP450 2D6 substrateNon-substrate0.7656
CYP450 3A4 substrateNon-substrate0.6059
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7344
Ames testNon AMES toxic0.6794
CarcinogenicityNon-carcinogens0.7294
BiodegradationNot ready biodegradable0.9837
Rat acute toxicity1.8148 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9319
hERG inhibition (predictor II)Non-inhibitor0.8591
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-03di-0009000000-2a72173931dce5701622
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-03di-0119000000-4abf1963718d72f73f59
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-001i-9351000000-b43658e112020008b9f9
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-001i-9100000000-4d303174266311856c28
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-001i-9000000000-2d120289f52c86515bea
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-014i-0009000000-97827d479a3470c40d42
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-015c-0396000000-5edaaa0fcc7cd3681c24
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-000x-0980000000-0b360ca9bf4e58649db7
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-053s-0910000000-c5fc710abfdf5947bc62
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0a4j-0900000000-368c9661bc6dfd8a8d83
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-000x-0291000000-134f42a8645c2f1b9bc5
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0009000000-e4d18d4c63310d0528db
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000x-0390000000-abfea32acc207ff88b1f
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-053r-0930000000-cc33040126bfe7cb08fa
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a5a-0910000000-42b9627a1135073b6ce1
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0ars-0900000000-d22f5ff182cd71ced792
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00lu-0594000000-78579410f8f6799b400b
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00lu-1694000000-dbf4d76ea1a12ee57935
MS/MS Spectrum - , positiveLC-MS/MSsplash10-053s-2920000000-ecd6db66d16ce8f483b8

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylethers. These are aromatic compounds containing two benzene rings linked to each other through an ether group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylethers
Direct Parent
Diphenylethers
Alternative Parents
Aminobenzenesulfonamides / Diarylethers / Aminobenzoic acids / Benzenesulfonyl compounds / Benzoic acids / Phenylalkylamines / Aniline and substituted anilines / Phenoxy compounds / Phenol ethers / Benzoyl derivatives
show 9 more
Substituents
Diphenylether / Aminobenzenesulfonamide / Diaryl ether / Aminobenzoic acid / Aminobenzoic acid or derivatives / Benzenesulfonamide / Benzoic acid or derivatives / Benzenesulfonyl group / Benzoic acid / Phenoxy compound
show 27 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
sulfonamide, benzoic acids, amino acid (CHEBI:3213)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Sodium:potassium:chloride symporter activity
Specific Function
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name
SLC12A1
Uniprot ID
Q13621
Uniprot Name
Solute carrier family 12 member 1
Molecular Weight
121449.13 Da
References
  1. Thakker RV: Chloride channels in renal disease. Adv Nephrol Necker Hosp. 1999;29:289-98. [PubMed:10561751]
  2. Karolyi L, Koch MC, Grzeschik KH, Seyberth HW: The molecular genetic approach to "Bartter's syndrome". J Mol Med (Berl). 1998 Apr;76(5):317-25. [PubMed:9587066]
  3. Thakker RV: The role of renal chloride channel mutations in kidney stone disease and nephrocalcinosis. Curr Opin Nephrol Hypertens. 1998 Jul;7(4):385-8. [PubMed:9690036]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  5. Long P, Mercer A, Begum R, Stephens GJ, Sihra TS, Jovanovic JN: Nerve Terminal GABAA Receptors Activate Ca2+/Calmodulin-dependent Signaling to Inhibit Voltage-gated Ca2+ Influx and Glutamate Release. J Biol Chem. 2009 Mar 27;284(13):8726-37. doi: 10.1074/jbc.M805322200. Epub 2009 Jan 13. [PubMed:19141616]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Sodium:potassium:chloride symporter activity
Specific Function
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name
SLC12A2
Uniprot ID
P55011
Uniprot Name
Solute carrier family 12 member 2
Molecular Weight
131445.825 Da
References
  1. Panet R, Marcus M, Atlan H: Overexpression of the Na(+)/K(+)/Cl(-) cotransporter gene induces cell proliferation and phenotypic transformation in mouse fibroblasts. J Cell Physiol. 2000 Jan;182(1):109-18. [PubMed:10567922]
  2. Evans RL, Park K, Turner RJ, Watson GE, Nguyen HV, Dennett MR, Hand AR, Flagella M, Shull GE, Melvin JE: Severe impairment of salivation in Na+/K+/2Cl- cotransporter (NKCC1)-deficient mice. J Biol Chem. 2000 Sep 1;275(35):26720-6. [PubMed:10831596]
  3. Wall SM, Fischer MP, Mehta P, Hassell KA, Park SJ: Contribution of the Na+-K+-2Cl- cotransporter NKCC1 to Cl- secretion in rat OMCD. Am J Physiol Renal Physiol. 2001 May;280(5):F913-21. [PubMed:11292635]
  4. Akar F, Jiang G, Paul RJ, O'Neill WC: Contractile regulation of the Na(+)-K(+)-2Cl(-) cotransporter in vascular smooth muscle. Am J Physiol Cell Physiol. 2001 Aug;281(2):C579-84. [PubMed:11443057]
  5. Jiang G, Klein JD, O'Neill WC: Growth factors stimulate the Na-K-2Cl cotransporter NKCC1 through a novel Cl(-)-dependent mechanism. Am J Physiol Cell Physiol. 2001 Dec;281(6):C1948-53. [PubMed:11698253]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Protein kinase binding
Specific Function
Mediates electroneutral potassium-chloride cotransport when activated by cell swelling. May contribute to cell volume homeostasis in single cells. May be involved in the regulation of basolateral C...
Gene Name
SLC12A4
Uniprot ID
Q9UP95
Uniprot Name
Solute carrier family 12 member 4
Molecular Weight
120648.73 Da
References
  1. Jean-Xavier C, Pflieger JF, Liabeuf S, Vinay L: Inhibitory postsynaptic potentials in lumbar motoneurons remain depolarizing after neonatal spinal cord transection in the rat. J Neurophysiol. 2006 Nov;96(5):2274-81. Epub 2006 Jun 28. [PubMed:16807348]
  2. Reid KH, Guo SZ, Iyer VG: Agents which block potassium-chloride cotransport prevent sound-triggered seizures in post-ischemic audiogenic seizure-prone rats. Brain Res. 2000 May 2;864(1):134-7. [PubMed:10793196]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Protein kinase binding
Specific Function
Mediates electroneutral potassium-chloride cotransport in mature neurons. Transport occurs under isotonic conditions, but is activated 20-fold by cell swelling. Important for Cl(-) homeostasis in n...
Gene Name
SLC12A5
Uniprot ID
Q9H2X9
Uniprot Name
Solute carrier family 12 member 5
Molecular Weight
126182.49 Da
References
  1. Reid KH, Guo SZ, Iyer VG: Agents which block potassium-chloride cotransport prevent sound-triggered seizures in post-ischemic audiogenic seizure-prone rats. Brain Res. 2000 May 2;864(1):134-7. [PubMed:10793196]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Pdz domain binding
Specific Function
Involved in the transport of chloride ions. May regulate bicarbonate secretion and salvage in epithelial cells by regulating the SLC4A7 transporter. Can inhibit the chloride channel activity of ANO...
Gene Name
CFTR
Uniprot ID
P13569
Uniprot Name
Cystic fibrosis transmembrane conductance regulator
Molecular Weight
168139.895 Da
References
  1. Reddy MM, Quinton PM: Bumetanide blocks CFTR GCl in the native sweat duct. Am J Physiol. 1999 Jan;276(1 Pt 1):C231-7. [PubMed:9886939]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Cheng HF, Wang JL, Zhang MZ, McKanna JA, Harris RC: Role of p38 in the regulation of renal cortical cyclooxygenase-2 expression by extracellular chloride. J Clin Invest. 2000 Sep;106(5):681-8. [PubMed:10974021]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Virus receptor activity
Specific Function
The hepatic sodium/bile acid uptake system exhibits broad substrate specificity and transports various non-bile acid organic compounds as well. It is strictly dependent on the extracellular presenc...
Gene Name
SLC10A1
Uniprot ID
Q14973
Uniprot Name
Sodium/bile acid cotransporter
Molecular Weight
38118.64 Da
References
  1. Hagenbuch B, Stieger B, Foguet M, Lubbert H, Meier PJ: Functional expression cloning and characterization of the hepatocyte Na+/bile acid cotransport system. Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10629-33. [PubMed:1961729]
  2. Platte HD, Honscha W, Schuh K, Petzinger E: Functional characterization of the hepatic sodium-dependent taurocholate transporter stably transfected into an immortalized liver-derived cell line and V79 fibroblasts. Eur J Cell Biol. 1996 May;70(1):54-60. [PubMed:8738419]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Race JE, Grassl SM, Williams WJ, Holtzman EJ: Molecular cloning and characterization of two novel human renal organic anion transporters (hOAT1 and hOAT3). Biochem Biophys Res Commun. 1999 Feb 16;255(2):508-14. [PubMed:10049739]
  2. Uwai Y, Saito H, Hashimoto Y, Inui KI: Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1. J Pharmacol Exp Ther. 2000 Oct;295(1):261-5. [PubMed:10991988]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
References
  1. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. [PubMed:11306713]
  2. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999 May 7;274(19):13675-80. [PubMed:10224140]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name
SLC22A11
Uniprot ID
Q9NSA0
Uniprot Name
Solute carrier family 22 member 11
Molecular Weight
59970.945 Da
References
  1. Cha SH, Sekine T, Kusuhara H, Yu E, Kim JY, Kim DK, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J Biol Chem. 2000 Feb 11;275(6):4507-12. [PubMed:10660625]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulf...
Gene Name
SLC22A7
Uniprot ID
Q9Y694
Uniprot Name
Solute carrier family 22 member 7
Molecular Weight
60025.025 Da
References
  1. Sekine T, Cha SH, Tsuda M, Apiwattanakul N, Nakajima N, Kanai Y, Endou H: Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. 1998 Jun 12;429(2):179-82. [PubMed:9650585]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Horz JA, Honscha W, Petzinger E: Bumetanide is not transported by the Ntcp or by the oatp: evidence for a third organic anion transporter in rat liver cells. Biochim Biophys Acta. 1996 Apr 19;1300(2):114-8. [PubMed:8652636]

Drug created on June 13, 2005 07:24 / Updated on May 26, 2018 08:51